Evidence map›Paper›PMID 26804755›Full record

ArticleThe Journal of urology2016

Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.

George R Schade, Sarah K Holt, Xiaotun Zhang, Dan Song, Jonathan L Wright, Shanshan Zhao, Suzanne Kolb, Hung-Ming Lam, Linda Levin, Yuet-Kin Leung and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

George R SchadeDepartment of Urology, School of Medicine, University of Washington, Seattle, Washington. Electronic address: grschade@uw.edu.
Sarah K HoltDepartment of Urology, School of Medicine, University of Washington, Seattle, Washington.
Xiaotun ZhangDepartment of Urology, School of Medicine, University of Washington, Seattle, Washington.
Dan SongDivision of Environmental Genetics and Molecular Toxicology, University of Cincinnati College of Medicine, Cincinnati Cancer Institute, Cincinnati, Ohio.
Jonathan L WrightDepartment of Urology, School of Medicine, University of Washington, Seattle, Washington; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Shanshan ZhaoDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Suzanne KolbDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Hung-Ming LamDepartment of Urology, School of Medicine, University of Washington, Seattle, Washington.
Linda LevinDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Yuet-Kin LeungCenter for Environmental Genetics and Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati Cancer Institute, Cincinnati, Ohio.
Shuk-Mei HoDivision of Environmental Genetics and Molecular Toxicology, University of Cincinnati College of Medicine, Cincinnati Cancer Institute, Cincinnati, Ohio; Center for Environmental Genetics and Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati Cancer Institute, Cincinnati, Ohio.
Janet L StanfordDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, Washington; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
NSAIDS and Other Medications in Prostate Cancer EtiologyR01CA092579 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2001 to 2005
$3.2M
Application of Statistical Methods in Epidemiology StudiesZIAES103308 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ZHAO, SHANSHAN · 2015 to 2025
$2.2M
Estrogen Pathway Genes and Association with Prostate Cancer RiskR03CA137799 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2008 to 2009
$176k
PROSTATE CANCER IN RELATION TO VASECTOMYR01CA056678 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1993 to 1997
–
NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA092579NCI NIH HHS R03 CA137799
6 · The paper itself

Abstract

purposeExisting data regarding the expression of estrogen receptors (ERs) and prostate cancer outcomes have been limited. We evaluated the relationship of expression profiles of ERβ subtypes and the ER GPR30 (G-protein-coupled receptor-30) with patient factors at diagnosis and outcomes following radical prostatectomy. MATERIALS AND

methodsTissue microarrays constructed using samples from 566 men with long-term clinical followup were analyzed by immunohistochemistry targeting ERβ1, ERβ2, ERβ5 and GPR30. An experienced pathologist scored receptor distribution and staining intensity. Tumor staining characteristics were evaluated for associations with patient characteristics, recurrence-free survival and prostate cancer specific mortality following radical prostatectomy.

resultsProstate cancer cells had unique receptor subtype staining patterns. ERβ1 demonstrated predominantly nuclear localization while ERβ2, ERβ5 and GPR30 were predominantly cytoplasmic. After controlling for patient factors intense cytoplasmic ERβ1 staining was independently associated with time to recurrence (HR 1.7, 95% CI 1.1-2.6, p = 0.01) and prostate cancer specific mortality (HR 6.6, 95% CI 1.8-24.9, p = 0.01). Intense nuclear ERβ2 staining was similarly independently associated with prostate cancer specific mortality (HR 3.9, 95% CI 1.1-13.4, p = 0.03). Patients with cytoplasmic ERβ1 and nuclear ERβ2 co-staining had significantly worse 15-year prostate cancer specific mortality than patients with expression of only cytoplasmic ERβ1, only nuclear ERβ2 and neither ER (16.4%, 4.3%, 0.0% and 2.0 %, respectively, p = 0.001).

conclusionsIncreased cytoplasmic ERβ1 and nuclear ERβ2 expression is associated with worse cancer specific outcomes following radical prostatectomy. These findings suggest that tumor ERβ1 and ERβ2 staining patterns provide prognostic information on patients treated with radical prostatectomy.

Indexed as

AdultAgedEstrogen Receptor betaHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProstateProstatectomyProstatic NeoplasmsReceptors, EstrogenReceptors, G-Protein-CoupledRetrospective StudiesSurvival AnalysisEstrogen Receptor betaGPER1 protein, humanReceptors, EstrogenReceptors, G-Protein-Coupledprognosisprostatectomyprostatic neoplasmsreceptors, estrogentissue array analysis

Identifiers

PMID26804755
PMCPMC4871721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.